DE EN Try for free

About AIRAmed

AIRAmed GmbH develops AIRAscore, AI-based brain volumetry software. The company was founded in May 2025 by the neuroradiologists Tobias Lindig and Benjamin Bender, the business economist Christiane Lindig and Johannes Schmidt-Tophoff, representing the majority shareholder Synamed GmbH, Heidelberg. The managing director is Johannes Schmidt-Tophoff, the authorised signatory (Prokurist) is Sebastian Penhouet. AIRAscore goes back to the work of Tobias Lindig and Benjamin Bender at Tübingen University Hospital.

What we work for

For physicians in radiology, neurology and psychiatry: we automate the volume measurement that is otherwise done by hand, so more time is left for their patients.1

For patients: we bring research results into care quickly, so that diagnosis and follow-up rest on objective measurements.

Milestones

  1. June 2020

    First CE marking of AIRAscore as a medical device under Directive 93/42/EEC (MDD)2

  2. August 2023

    FDA 510(k) clearance for AIRAscore 2.1.03

  3. November 2024

    CE marking under Regulation (EU) 2017/745 (MDR), replacing the certification under the MDD4

  4. May 2025

    AIRAmed GmbH founded

  5. 202612 partners at 31 sites in Germany

Research

AIRAscore is used in clinical research, for example in hereditary spastic paraplegia5,6 and in a genetic form of Parkinson’s disease7. In a comparison of seven programs on six MRI scanners, grey and white matter volumes from repeated scans of the same people varied by a median of less than 0.2% with AIRAscore.8

Our values

  • Patient safety
  • University excellence
  • Innovation
  • Customer satisfaction
  • Togetherness
  • Improvement
  • Fun at work

Your contacts

General enquiries: info@airamed.de

Sources (8)
  1. AIRAscore instructions for use 3.1.0, section 1.1: the software is meant to automate the manual process of identifying, labelling and quantifying the volume of brain structures. Source
  2. AIRAscore instructions for use 2.1.0, chapter 1 and labelling: CE mark under Directive 93/42/EEC (MDD), notified body 0633 (BerlinCert). Source
  3. FDA 510(k) K223180, cleared on 25 August 2023. The clearance covers AIRAscore version 2.1.0 only. Source
  4. CE mark under Regulation (EU) 2017/745 (MDR), notified body 0633 (BerlinCert).
  5. Lindig T, Bender B, Bürkle E, et al. Proof of principle for the clinical use of a CE-certified automatic imaging analysis tool in rare diseases studying hereditary spastic paraplegia type 4 (SPG4). Scientific Reports 2022; 12: 22075. Source
  6. Rattay TW, Völker M, Rautenberg M, et al. The prodromal phase of hereditary spastic paraplegia type 4: the preSPG4 cohort study. Brain 2023; 146: 1093–1102. Source
  7. Wurster I, Quadalti C, Rossi M, et al. Linking the phenotype of SNCA triplication with PET-MRI imaging pattern and alpha-synuclein CSF seeding. npj Parkinson’s Disease 2022; 8: 117. Source
  8. Bürkle E, Nazzal A, Debolski A, Ernemann U, Lindig T, Bender B. Scan-rescan reliability assessment of brain volumetric analysis across scanners and software solutions. Scientific Reports 2025; 15: 29843. Source